72573-82-1

Basic information

• Product Name: Gadoteric acid
• Synonyms: Gadoteric acid;Gadoteric;Gadolinium 2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetic acid;Gadolinate(1-),[1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetato(4-)-kN1,kN4,kN7,kN10,kO1,kO4,kO7,kO10]-, hydrogen (1:1)
• CAS NO: 72573-82-1
• Molecular Formula: C₁₆H₂₅GdN₄O₈
• Molecular Weight: 558.65
• EINECS: 1533716-785-6
• Mol File: 72573-82-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 701.6 ºC at 760 mmHg
• Flash Point: 378.1 ºC
• Appearance: /
• Vapor Pressure: 1.51E-21mmHg at 25°C
• Storage Temp.: Refrigerator
• Solubility: Water (Slightly)
• CAS DataBase Reference: Gadoteric acid(CAS DataBase Reference)
• NIST Chemistry Reference: Gadoteric acid(72573-82-1)
• EPA Substance Registry System: Gadoteric acid(72573-82-1)

Safety Data

• Hazardous Substances Data: 72573-82-1(Hazardous Substances Data)

Usage

Uses

Gadoteric Acid is used for magnetic resonance imaging.

Definition

ChEBI: A gadolinium coordination entity consisting of DOTA in which the four amino groups are bound to a central gadolinium atom. It is used (as its meglumine salt) in magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues of patie ts ages 2 years and older, to detect and visualise areas with disruption of the blood brain barrier and/or abnormal vascularity of the central nervous system.

InChI:InChI=1/C16H28N4O8.Gd/c21-13(22)9-17-1-2-18(10-14(23)24)5-6-20(12-16(27)28)8-7-19(4-3-17)11-15(25)26;/h1-12H2,(H,21,22)(H,23,24)(H,25,26)(H,27,28);/q;+3

Synthetic route

gadolinium(III) oxide + 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (60239-18-1) → gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (72573-82-1)

Conditions	Yield
In water for 3h;	67.9%
In water addn. of gadolinium oxide to aq. soln. of tetraazacyclododecane deriv., mixt. heated at 90°C for 12 h; cooling to room temp., addn. of cation-exchange and anion-exchange resins, stirring for 60 min at room temp., filtration, filtrate freeze dried;	61%

1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane (60239-18-1) + gadolinium(III) chloride hexahydrate → gadolinium(III) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (72573-82-1)

Conditions	Yield
With ammonium acetate In water at 37℃; for 2h; pH=8.5;

Upstream product

• 60239-18-1 1,4,7,10-tetrakis(carboxymethyl)-1,4,7,10-tetraazacyclododecane 

Relevant articles and documents

Fragmentation behavior of DOTA complexes under different activation conditions

We have investigated the fragmentation behavior of a number of DOTA-metal complexes under collision-induced dissociation, infrared-multiphoton dissociation and higher-energy collisional dissociation activation conditions. Both, positive and negative ion mode electrospray ionization was applied. The results show that characteristic fragmentations were obtained for the metal-complexes under the investigated conditions. All elemental compositions of fragment ions have been unambiguously identified by high resolution-accurate mass measurements. Certain trends, for instance eliminations of carbon dioxide, alkyl and amine residues, were observed that coincide with the size of the metal and its location within the periodic table. Additionally, lanthanide, aluminium and indium species with even oxidation state or containing a radical have been detected. To further investigate the observed water capture during activation, deuterium labeling experiments have also been carried out. Copyright

Preparation method for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid

The invention relates to a preparation method for 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Specifically, the method uses a recrystallization method to obtain a high-purity compound represented by a formula I shown in the description, and further, meglumine and Gd2O3 are complexed with the compound represented by the formula I to obtain the gadoteric acid meglumine. The method disclosed by the invention is simple to operate, has low costs, and is green, environmentally friendly and suitable for large-scale production.

Process for preparing contrast agent for magnetic resonance imaging

The present invention relates to a method for manufacturing a contrast agent for magnetic resonance imaging (MRI) and, more specifically, to a method for manufacturing a contrast agent for magnetic resonance imaging (MRI), having improved stability by minimizing side effects by removing an unreacted substance generated in a manufacturing process. The manufacturing method comprises the following steps: forming a complex-containing aqueous solution by reacting lantanide and macrocyclic chelate; exchanging ions by using one or more resin among cation exchange resin, chelate resin, and anion exchange resin for removing free lantanide and unreacted macrocyclic chelate from the complex-containing aqueous solution; controlling pH of the complex aqueous solution into a neutral range; and removing germs in the complex aqueous solution.